Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 10 | 2023 | 2193 | 1.550 |
Why?
|
Apolipoprotein A-I | 10 | 2024 | 305 | 1.500 |
Why?
|
Lipoproteins, HDL | 10 | 2024 | 678 | 1.040 |
Why?
|
Coated Materials, Biocompatible | 2 | 2024 | 314 | 0.960 |
Why?
|
Secondary Prevention | 5 | 2024 | 1469 | 0.860 |
Why?
|
Benzamides | 8 | 2019 | 1375 | 0.780 |
Why?
|
Coronary Restenosis | 1 | 2024 | 396 | 0.750 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 349 | 0.680 |
Why?
|
Enoxaparin | 7 | 2019 | 391 | 0.680 |
Why?
|
Thrombolytic Therapy | 2 | 2018 | 2053 | 0.640 |
Why?
|
Myocardial Infarction | 11 | 2024 | 11514 | 0.640 |
Why?
|
Angioplasty, Balloon | 1 | 2022 | 592 | 0.620 |
Why?
|
Anticoagulants | 9 | 2021 | 4854 | 0.610 |
Why?
|
Coronary Circulation | 1 | 2024 | 1602 | 0.590 |
Why?
|
Cardiovascular Agents | 1 | 2024 | 849 | 0.580 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2024 | 1721 | 0.560 |
Why?
|
Venous Thromboembolism | 8 | 2018 | 1883 | 0.550 |
Why?
|
Pyridines | 9 | 2019 | 2888 | 0.520 |
Why?
|
Collateral Circulation | 1 | 2017 | 289 | 0.510 |
Why?
|
Venous Thrombosis | 5 | 2018 | 1321 | 0.480 |
Why?
|
Students, Nursing | 1 | 2015 | 45 | 0.470 |
Why?
|
Coronary Artery Disease | 3 | 2024 | 6575 | 0.470 |
Why?
|
Education, Nursing | 1 | 2015 | 84 | 0.470 |
Why?
|
Plaque, Atherosclerotic | 2 | 2023 | 1549 | 0.470 |
Why?
|
Troponin | 1 | 2017 | 536 | 0.450 |
Why?
|
Carotid Arteries | 1 | 2016 | 932 | 0.380 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2021 | 2763 | 0.360 |
Why?
|
Renal Dialysis | 3 | 2017 | 1790 | 0.360 |
Why?
|
Education, Medical, Undergraduate | 2 | 2016 | 1087 | 0.320 |
Why?
|
Double-Blind Method | 15 | 2024 | 12430 | 0.320 |
Why?
|
Vitamin K 2 | 2 | 2019 | 47 | 0.310 |
Why?
|
Acute Disease | 5 | 2017 | 7240 | 0.300 |
Why?
|
Hemorrhage | 8 | 2021 | 3464 | 0.300 |
Why?
|
Pulmonary Embolism | 3 | 2017 | 2596 | 0.300 |
Why?
|
Fibrinolytic Agents | 3 | 2021 | 2078 | 0.290 |
Why?
|
Atrial Fibrillation | 4 | 2021 | 5182 | 0.290 |
Why?
|
Teaching | 1 | 2015 | 1171 | 0.280 |
Why?
|
Thrombosis | 2 | 2017 | 2953 | 0.270 |
Why?
|
Tissue and Organ Procurement | 1 | 2015 | 987 | 0.270 |
Why?
|
Treatment Outcome | 18 | 2024 | 65286 | 0.260 |
Why?
|
Cardiovascular Diseases | 8 | 2024 | 15652 | 0.250 |
Why?
|
Students, Medical | 2 | 2016 | 1962 | 0.240 |
Why?
|
Cholesterol | 6 | 2023 | 2904 | 0.240 |
Why?
|
Patient Readmission | 1 | 2018 | 3283 | 0.230 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3692 | 0.210 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3927 | 0.200 |
Why?
|
Humans | 57 | 2024 | 766812 | 0.200 |
Why?
|
Coronary Angiography | 2 | 2024 | 4525 | 0.200 |
Why?
|
Infusions, Intravenous | 5 | 2024 | 2228 | 0.190 |
Why?
|
Vascular Resistance | 1 | 2024 | 939 | 0.180 |
Why?
|
Vascular Patency | 1 | 2024 | 915 | 0.180 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 10745 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4056 | 0.170 |
Why?
|
Cholesterol, LDL | 3 | 2024 | 2392 | 0.170 |
Why?
|
Vitamin K | 3 | 2017 | 314 | 0.170 |
Why?
|
Drug-Eluting Stents | 2 | 2024 | 681 | 0.170 |
Why?
|
Heart Failure | 3 | 2018 | 11879 | 0.170 |
Why?
|
Drug Therapy, Combination | 3 | 2018 | 6306 | 0.170 |
Why?
|
Microcirculation | 1 | 2024 | 1282 | 0.160 |
Why?
|
Vascular Diseases | 2 | 2017 | 1161 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2020 | 242 | 0.150 |
Why?
|
Extracellular Matrix Proteins | 2 | 2019 | 833 | 0.150 |
Why?
|
Calcium-Binding Proteins | 2 | 2019 | 1080 | 0.140 |
Why?
|
Vitamin K Deficiency | 1 | 2017 | 24 | 0.140 |
Why?
|
Education | 1 | 2020 | 531 | 0.140 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5536 | 0.140 |
Why?
|
International Normalized Ratio | 1 | 2018 | 382 | 0.140 |
Why?
|
Antidotes | 1 | 2017 | 138 | 0.130 |
Why?
|
Kidney Failure, Chronic | 3 | 2018 | 2505 | 0.130 |
Why?
|
Ondansetron | 1 | 2017 | 95 | 0.130 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2017 | 128 | 0.130 |
Why?
|
Equipment Design | 1 | 2024 | 3488 | 0.130 |
Why?
|
Factor Xa | 1 | 2017 | 165 | 0.130 |
Why?
|
Atherosclerosis | 2 | 2022 | 3421 | 0.130 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2016 | 42 | 0.130 |
Why?
|
Multilingualism | 1 | 2016 | 88 | 0.130 |
Why?
|
Kidney Tubules | 1 | 2018 | 454 | 0.130 |
Why?
|
Creatine Kinase, MB Form | 1 | 2016 | 203 | 0.130 |
Why?
|
Stroke | 6 | 2024 | 9744 | 0.120 |
Why?
|
Kidney Glomerulus | 1 | 2018 | 571 | 0.120 |
Why?
|
Risk Factors | 9 | 2024 | 74889 | 0.120 |
Why?
|
Paclitaxel | 1 | 2022 | 1728 | 0.120 |
Why?
|
Haloperidol | 1 | 2017 | 394 | 0.120 |
Why?
|
Antiemetics | 1 | 2017 | 187 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4853 | 0.110 |
Why?
|
Oligopeptides | 2 | 2016 | 1195 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 6 | 2024 | 6514 | 0.110 |
Why?
|
Nurse's Role | 1 | 2015 | 187 | 0.110 |
Why?
|
Ambulatory Care | 1 | 2024 | 2779 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 984 | 0.100 |
Why?
|
Medical History Taking | 1 | 2016 | 779 | 0.100 |
Why?
|
Aged | 20 | 2024 | 171344 | 0.100 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2015 | 426 | 0.100 |
Why?
|
Coronary Vessels | 1 | 2024 | 3115 | 0.100 |
Why?
|
Transplants | 1 | 2015 | 209 | 0.100 |
Why?
|
Male | 29 | 2024 | 364154 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 962 | 0.100 |
Why?
|
Conflict of Interest | 1 | 2017 | 556 | 0.100 |
Why?
|
Troponin I | 1 | 2016 | 659 | 0.100 |
Why?
|
Female | 29 | 2024 | 396532 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1134 | 0.090 |
Why?
|
Time Factors | 6 | 2021 | 40149 | 0.090 |
Why?
|
Kidney Transplantation | 2 | 2017 | 4278 | 0.090 |
Why?
|
Risk Assessment | 4 | 2022 | 24299 | 0.090 |
Why?
|
Warfarin | 1 | 2018 | 1493 | 0.090 |
Why?
|
Diabetic Nephropathies | 1 | 2017 | 975 | 0.080 |
Why?
|
Administration, Oral | 1 | 2017 | 4019 | 0.080 |
Why?
|
Anesthesia, General | 1 | 2017 | 1188 | 0.080 |
Why?
|
Emergency Medical Services | 1 | 2021 | 1936 | 0.080 |
Why?
|
Anemia, Sickle Cell | 1 | 2018 | 1063 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2018 | 39312 | 0.080 |
Why?
|
Cardiology | 1 | 2020 | 1701 | 0.080 |
Why?
|
Vitamins | 1 | 2017 | 1631 | 0.080 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1750 | 0.080 |
Why?
|
Antioxidants | 1 | 2016 | 1671 | 0.080 |
Why?
|
Physician's Role | 1 | 2015 | 925 | 0.070 |
Why?
|
Middle Aged | 15 | 2024 | 223267 | 0.070 |
Why?
|
Hospitalization | 5 | 2021 | 10816 | 0.070 |
Why?
|
Stents | 2 | 2016 | 3193 | 0.070 |
Why?
|
Cause of Death | 1 | 2018 | 3717 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2662 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6507 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1194 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 418 | 0.070 |
Why?
|
Migraine Disorders | 1 | 2019 | 1710 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2101 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6329 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2018 | 1946 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2016 | 1456 | 0.060 |
Why?
|
Prospective Studies | 4 | 2018 | 54872 | 0.060 |
Why?
|
Recurrence | 3 | 2024 | 8507 | 0.060 |
Why?
|
Cholesterol, HDL | 2 | 2022 | 1814 | 0.060 |
Why?
|
Tissue Donors | 1 | 2015 | 2392 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2017 | 5143 | 0.060 |
Why?
|
Societies, Medical | 1 | 2017 | 3957 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2306 | 0.060 |
Why?
|
Glomerular Filtration Rate | 3 | 2018 | 2232 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10384 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2016 | 3831 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8734 | 0.050 |
Why?
|
Incidence | 2 | 2018 | 21527 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12536 | 0.050 |
Why?
|
Kidney | 2 | 2016 | 7073 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3110 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3232 | 0.050 |
Why?
|
Creatinine | 2 | 2018 | 1917 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3459 | 0.050 |
Why?
|
Curriculum | 1 | 2015 | 3783 | 0.050 |
Why?
|
Phosphatidylcholines | 1 | 2022 | 404 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2022 | 385 | 0.040 |
Why?
|
Adult | 10 | 2019 | 223305 | 0.040 |
Why?
|
Biological Transport | 1 | 2022 | 2083 | 0.040 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2018 | 109 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.040 |
Why?
|
Migraine with Aura | 1 | 2019 | 203 | 0.040 |
Why?
|
Aftercare | 1 | 2023 | 915 | 0.040 |
Why?
|
Western World | 1 | 2016 | 26 | 0.030 |
Why?
|
Organizational Innovation | 1 | 2020 | 540 | 0.030 |
Why?
|
Hydroxyurea | 1 | 2018 | 284 | 0.030 |
Why?
|
Hematuria | 1 | 2018 | 232 | 0.030 |
Why?
|
United States | 3 | 2020 | 72945 | 0.030 |
Why?
|
Lebanon | 1 | 2016 | 246 | 0.030 |
Why?
|
Half-Life | 1 | 2016 | 648 | 0.030 |
Why?
|
Renal Replacement Therapy | 1 | 2018 | 282 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10101 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.030 |
Why?
|
Sample Size | 1 | 2018 | 844 | 0.030 |
Why?
|
Bilirubin | 1 | 2016 | 440 | 0.030 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2016 | 285 | 0.030 |
Why?
|
Chick Embryo | 1 | 2016 | 973 | 0.030 |
Why?
|
Triglycerides | 1 | 2022 | 2441 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2016 | 608 | 0.030 |
Why?
|
Lactones | 1 | 2016 | 316 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2016 | 15831 | 0.030 |
Why?
|
Research Design | 2 | 2022 | 6206 | 0.030 |
Why?
|
Electrocardiography | 2 | 2017 | 6408 | 0.030 |
Why?
|
Placebo Effect | 1 | 2016 | 515 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2018 | 59548 | 0.020 |
Why?
|
Medication Adherence | 1 | 2023 | 2190 | 0.020 |
Why?
|
Intracranial Hemorrhages | 1 | 2017 | 810 | 0.020 |
Why?
|
Medical Records | 1 | 2017 | 1408 | 0.020 |
Why?
|
Comprehension | 1 | 2016 | 638 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2921 | 0.020 |
Why?
|
Blood Coagulation | 1 | 2017 | 1163 | 0.020 |
Why?
|
Analgesics | 1 | 2018 | 1068 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2016 | 746 | 0.020 |
Why?
|
Angiography | 1 | 2016 | 1595 | 0.020 |
Why?
|
Clinical Clerkship | 1 | 2016 | 569 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3466 | 0.020 |
Why?
|
Primary Prevention | 1 | 2017 | 1188 | 0.020 |
Why?
|
Schools, Medical | 1 | 2016 | 882 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 3250 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36570 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9602 | 0.020 |
Why?
|
Inpatients | 1 | 2017 | 2566 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2017 | 26309 | 0.020 |
Why?
|
Critical Illness | 1 | 2017 | 2750 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2017 | 3429 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8728 | 0.010 |
Why?
|
Myocardium | 1 | 2016 | 4765 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22248 | 0.010 |
Why?
|
Graft Rejection | 1 | 2015 | 4504 | 0.010 |
Why?
|
Blood Pressure | 1 | 2017 | 8533 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14653 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 59939 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7571 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15835 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15425 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18397 | 0.010 |
Why?
|
Smoking | 1 | 2015 | 9077 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20146 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29959 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8616 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 41706 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2021 | 81657 | 0.010 |
Why?
|
Animals | 1 | 2016 | 168939 | 0.000 |
Why?
|
Concepts
(216)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_